NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis → AI “wealth window” is closing June 25th (From Paradigm Press) (Ad) Free ASMB Stock Alerts $12.95 +0.33 (+2.61%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$12.51▼$13.0550-Day Range$11.80▼$15.0652-Week Range$7.69▼$20.04Volume13,958 shsAverage Volume25,959 shsMarket Capitalization$71.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Assembly Biosciences alerts: Email Address Assembly Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.84% of Float Sold ShortDividend StrengthN/ASustainability-0.71Upright™ Environmental ScoreNews Sentiment0.10Based on 22 Articles This WeekInsider TradingSelling Shares$62,817 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($12.65) to ($13.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector651st out of 905 stocksPharmaceutical Preparations Industry301st out of 422 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Assembly Biosciences.Read more about Assembly Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.84% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 28.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAssembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Assembly Biosciences is -0.71. Previous Next 2.3 News and Social Media Coverage News SentimentAssembly Biosciences has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Assembly Biosciences this week, compared to 23 articles on an average week.Search Interest1 people have searched for ASMB on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,817.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.92% of the stock of Assembly Biosciences is held by institutions.Read more about Assembly Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($12.65) to ($13.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assembly Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Assembly Biosciences Stock (NASDAQ:ASMB)Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More ASMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASMB Stock News HeadlinesMay 2, 2024 | insidertrades.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Insider Sells $15,951.05 in StockMay 8, 2024 | msn.comAssembly sets school funding floorMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 8, 2024 | globenewswire.comAssembly Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsMay 7, 2024 | msn.comFreedom Caucus members putting General Assembly under tight deadlineMay 7, 2024 | msn.comBelvidere Assembly Plant alum Aubrey Moore takes the wheel on new electric ChargerMay 7, 2024 | msn.comAssembly backs two-day suspension for former UUP leader Steve AikenMay 7, 2024 | foxnews.comPalestinians pursue UN General Assembly support for full membership bidMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 6, 2024 | msn.comRivers Assembly Members Don’t Exist as Lawmakers, Says Governor FubaraMay 6, 2024 | afr.comLowy-backed Assembly names new chief investment officerMay 6, 2024 | msn.com'Just give 5 years to BJP, we will…': PM Modi says BJD govt will expire in Odisha after Assembly pollsMay 6, 2024 | msn.comAmaewhule-led Assembly snubs Fubara, passes another billMay 6, 2024 | msn.comAssembly Elections 2024 | Haryana CM Nayab Saini files nomination for Karnal assembly bypollMay 6, 2024 | msn.comLondon Assembly results as Sadiq Khan wins historic third term as mayorMay 5, 2024 | msn.comCandidate hosts State Assembly District 93 Kick-Off PartyMay 5, 2024 | msn.comHimachal NCP fields Ravindra Singh Dogra for Sujanpur Assembly bypollMay 4, 2024 | yahoo.comIncumbent Bronson takes aim at 'single-party rule' and Assembly in Anchorage mayoral runoff against LaFranceMay 4, 2024 | msn.comLaurence Fox loses deposit after failing to become London Assembly memberMay 4, 2024 | msn.comLondon mayoral election and London Assembly resultsMay 3, 2024 | msn.comRep. Elijah Behnke announces bid for 6th Assembly District, setting up Republican primaryMay 3, 2024 | americanbankingnews.comJason A. Okazaki Sells 1,569 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) StockMay 3, 2024 | americanbankingnews.comNicole S. White Sells 1,255 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) StockMay 3, 2024 | msn.comPak Harbours "Most Dubious Track Record" On All Aspects: India At UN General AssemblyMay 1, 2024 | msn.comCapital's smaller parties plan 'historic breakthrough' on London AssemblyMay 1, 2024 | msn.comMozambique: Assembly Amends Election LawsMay 1, 2024 | msn.comPDP urges Kaduna Assembly to investigate expenditure of El-Rufai govtSee More Headlines Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/08/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees65Year Founded2005Profitability EPS (Most Recent Fiscal Year)($17.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,230,000.00 Net MarginsN/A Pretax Margin-854.32% Return on Equity-117.69% Return on Assets-72.43% Debt Debt-to-Equity RatioN/A Current Ratio3.41 Quick Ratio3.41 Sales & Book Value Annual Sales$7.16 million Price / Sales9.91 Cash FlowN/A Price / Cash FlowN/A Book Value$7.50 per share Price / Book1.73Miscellaneous Outstanding Shares5,483,000Free Float5,203,000Market Cap$71.00 million OptionableOptionable Beta0.60 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jason A. Okazaki (Age 48)CEO, President & Director Comp: $869.28kDr. William E. Delaney IV (Age 52)Ph.D., Chief Scientific Officer Comp: $664.4kDr. Uri A. Lopatin M.D. (Age 52)Co-Founder and Clinical & Scientific Advisor Comp: $608.55kDr. Adam ZlotnickCo-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardJeanette M BjorkquistExecutive Director of Accounting & TreasuryShannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance ManagementMs. Jennifer A. Troia MHRODSHRM-SCP, SPHR, Chief Human Resources OfficerDr. Nicole S. White Ph.D.Chief Manufacturing OfficerDr. Anuj Gaggar M.D.Ph.D., Chief Medical OfficerMr. Thomas E. Rollins (Age 68)Executive Officer Comp: $472.55kMore ExecutivesKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXStrongbridge BiopharmaNASDAQ:SBBPOmerosNASDAQ:OMERNektar TherapeuticsNASDAQ:NKTRLandos BiopharmaNASDAQ:LABPView All CompetitorsInsiders & InstitutionsMarquette Asset Management LLCSold 45,448 shares on 5/7/2024Ownership: 0.165%Jason A OkazakiSold 1,569 sharesTotal: $19,941.99 ($12.71/share)Nicole S WhiteSold 1,255 sharesTotal: $15,951.05 ($12.71/share)John G MchutchisonSold 1,206 sharesTotal: $15,762.42 ($13.07/share)Jason A OkazakiSold 354 sharesTotal: $4,626.78 ($13.07/share)View All Insider TransactionsView All Institutional Transactions ASMB Stock Analysis - Frequently Asked Questions Should I buy or sell Assembly Biosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks. How have ASMB shares performed in 2024? Assembly Biosciences' stock was trading at $9.8412 at the beginning of 2024. Since then, ASMB shares have increased by 31.6% and is now trading at $12.95. View the best growth stocks for 2024 here. Are investors shorting Assembly Biosciences? Assembly Biosciences saw a decrease in short interest in April. As of April 15th, there was short interest totaling 30,600 shares, a decrease of 28.2% from the March 31st total of 42,600 shares. Based on an average trading volume of 27,700 shares, the short-interest ratio is currently 1.1 days. Currently, 0.8% of the company's shares are short sold. View Assembly Biosciences' Short Interest. When is Assembly Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ASMB earnings forecast. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.84) by $1.92. The biopharmaceutical company earned $6.25 million during the quarter. When did Assembly Biosciences' stock split? Shares of Assembly Biosciences reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is John McHutchison's approval rating as Assembly Biosciences' CEO? 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC). Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alexander Schornstein, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASMB) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.